Consun Pharmaceutical Group Gestione

Gestione criteri di controllo 3/4

Consun Pharmaceutical Group Il CEO è Meng An, nominato in Jan2024, e ha un mandato di meno di un anno. la retribuzione annua totale è CN¥ 19.79M, composta da 5.5% di stipendio e 94.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.74% delle azioni della società, per un valore di HK$ 186.80M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 4 anni.

Informazioni chiave

Meng An

Amministratore delegato

CN¥19.8m

Compenso totale

Percentuale dello stipendio del CEO	5.5%
Mandato del CEO	less than a year
Proprietà del CEO	2.7%
Durata media del management	4yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

Oct 02

Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

Sep 26

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Aug 26

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Apr 21

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Mar 17

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

Feb 19

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 29

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Jan 08

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Dec 18

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Nov 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Meng An rispetto agli utili di Consun Pharmaceutical Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	CN¥836m
Mar 31 2024	n/a	n/a	CN¥810m
Dec 31 2023	CN¥20m	CN¥1m	CN¥785m
Sep 30 2023	n/a	n/a	CN¥759m
Jun 30 2023	n/a	n/a	CN¥734m
Mar 31 2023	n/a	n/a	CN¥708m
Dec 31 2022	CN¥17m	CN¥1m	CN¥683m
Sep 30 2022	n/a	n/a	CN¥660m
Jun 30 2022	n/a	n/a	CN¥636m
Mar 31 2022	n/a	n/a	CN¥613m
Dec 31 2021	CN¥14m	CN¥670k	CN¥590m

Compensazione vs Mercato: La retribuzione totale di Meng ($USD 2.73M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 481.37K ).

Compensazione vs guadagni: La retribuzione di Meng è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Meng An (53 yo)

less than a year

Mandato

CN¥19,793,000

Compensazione

Mr. Meng An serves as Executive Chairman of the Board at Consun Pharmaceutical Group Limited since July 9, 2021 and serves a sits Chief Executive Officer from January 17, 2024. Mr. An being the Chairman of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Meng An	CEO & Executive Chairman	less than a year	CN¥19.79m	2.74% HK$ 186.8m
Quan Zhu	Chief Scientist & Executive Director	4yrs	CN¥742.00k	Nessun dato
Hanxing Xu	Assistant GM	3.7yrs	CN¥774.00k	Nessun dato
Peicheng Fang	CFO & VP	4.7yrs	Nessun dato	Nessun dato
Lei Zhou	Assistant President	4.8yrs	Nessun dato	Nessun dato
Haien Gao	Board Secretary	10.6yrs	Nessun dato	Nessun dato
Guorong Guo	Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd	4yrs	Nessun dato	Nessun dato
Lianhui Chen	Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd	4yrs	Nessun dato	Nessun dato

4.0yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di 1681 è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Meng An	CEO & Executive Chairman	3.7yrs	CN¥19.79m	2.74% HK$ 186.8m
Quan Zhu	Chief Scientist & Executive Director	11.9yrs	CN¥742.00k	Nessun dato
Hanxing Xu	Assistant GM	3.7yrs	CN¥774.00k	Nessun dato
Guorong Guo	Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd	4yrs	Nessun dato	Nessun dato
Lianhui Chen	Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd	4yrs	Nessun dato	Nessun dato
Zhongshi Feng	Independent Non-Executive Director	10.9yrs	CN¥200.00k	Nessun dato
Yujun Chen	Independent Non Executive Director	5.5yrs	CN¥200.00k	Nessun dato
Lihua Zhang	Non-Executive Director	3.3yrs	Nessun dato	Nessun dato
Yikai Li	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

4.0yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1681 sono considerati esperti (durata media dell'incarico 4 anni).

Consun Pharmaceutical Group Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CEO & Executive Chairman recently bought HK$5.4m worth of stock

Consun Pharmaceutical Group Limited Announces Executive Changes

CEO & Executive Chairman recently bought HK$7.7m worth of stock

Consun Pharmaceutical Group Limited Announces Board and Committee Changes

Chief Scientist & Executive Director recently sold HK$8.4m worth of stock

Insider recently sold HK$62m worth of stock

Recent updates

Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

First half 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.44 in 1H 2023)

Investor sentiment improves as stock rises 15%

Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

CEO & Executive Chairman recently bought HK$5.4m worth of stock

First half dividend of HK$0.30 announced

Consun Pharmaceutical Group Limited Announces Executive Changes

Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 September 2024

Consun Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Consun Pharmaceutical Group Limited Receives Notice of Approval for Clinical Trial of Drug for SK-08 Tablet

CEO & Executive Chairman recently bought HK$7.7m worth of stock

Consun Pharmaceutical Group Limited Announces Board and Committee Changes

Chief Scientist & Executive Director recently sold HK$8.4m worth of stock

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

New minor risk - Shareholder dilution

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Insider recently sold HK$62m worth of stock

Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Consun Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Consun Pharmaceutical Group Limited Announces Management Changes

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Upcoming dividend of HK$0.15 per share at 6.2% yield

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023

Consun Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 24, 2023

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.30 per share at 6.0% yield

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.31 in 1H 2021)

Consun Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Consun Pharmaceutical Group Limited, A Wholly-Owned Subsidiary of Consun Pharmaceutical (Horgos) Co., Ltd Holds A Trial Production Ceremony in Plant No. 8, Area A05, Horgos Comprehensive Bonded Zone, Yili Kazakh

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.20 per share

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.61 in FY 2020)

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on or About 17 June 2022

Less than half of directors are independent

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Investor sentiment improved over the past week

Upcoming dividend of HK$0.10 per share

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

First half 2021 earnings released: EPS CN¥0.31 (vs CN¥0.25 in 1H 2020)

Investor sentiment improved over the past week

Chairman of the Board Yubao An has left the company

Upcoming dividend of HK$0.20 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Investor sentiment improved over the past week

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Consun Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: HK$3.40

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly